<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7608025</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6790</journal-id>
<journal-id journal-id-type="nlm-ta">Psychopharmacology (Berl)</journal-id>
<journal-id journal-id-type="iso-abbrev">Psychopharmacology (Berl.)</journal-id>
<journal-title-group>
<journal-title>Psychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0033-3158</issn>
<issn pub-type="epub">1432-2072</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30392132</article-id>
<article-id pub-id-type="pmc">6286152</article-id>
<article-id pub-id-type="doi">10.1007/s00213-018-5099-x</article-id>
<article-id pub-id-type="manuscript">NIHMS1511516</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Vasopressin and alcohol: A multifaceted relationship</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Harper</surname>
<given-names>Kathryn M</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Knapp</surname>
<given-names>Darin J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Criswell</surname>
<given-names>Hugh E.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Breese</surname>
<given-names>George R.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Bowles Center for Alcohol Studies, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7178, USA</aff>
<aff id="A2"><label>2</label>Department of Psychiatry, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7178, USA</aff>
<aff id="A3"><label>3</label>Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7178, USA</aff>
<author-notes>
<corresp id="CR1"><label>*</label>Correspondence: Dr. Kathryn M Harper, Bowles Center for Alcohol Studies, Thurston Bowles Building, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7178, US</corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P37">The authors have no conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>6</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>03</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>235</volume>
<issue>12</issue>
<fpage>3363</fpage>
<lpage>3379</lpage>
<!--elocation-id from pubmed: 10.1007/s00213-018-5099-x-->
<abstract id="ABS1">
<sec id="S1">
<title>Background:</title>
<p id="P1">Arginine vasopressin (VP) has been implicated in a number of neuropsychiatric disorders with an emphasis on situations were stress increased the severity of the disorder. Based on this hypothesized role for VP in neuropsychiatric disorders, much research is currently being undertaken in humans and animals to test VP as a target for treatment of a number of these disorders including alcohol abuse.</p>
</sec>
<sec id="S2">
<title>Objectives:</title>
<p id="P2">To provide a summary of the literature regarding the role of VP in alcohol and stress related behaviors including the use of drugs that target VP in clinical trials.</p>
</sec>
<sec id="S3">
<title>Results:</title>
<p id="P3">Changes in various components of the VP system occur with alcohol and stress. Manipulating VP or its receptors can alter alcohol and stress related behaviors including tolerance to alcohol, alcohol drinking, and anxiety-like behavior. Finally, the HPA axis response to alcohol is also altered by manipulating the VP system. However, clinical trials of VP antagonists have had mixed results.</p>
</sec>
<sec id="S4">
<title>Conclusions:</title>
<p id="P4">A review of VP’s involvement in alcohol’s actions demonstrates that there is much to be learned about brain regions involved in VP-mediated effects on behavior. Thus, future work should focus on elucidating relevant brain regions. By using previous knowledge of the actions of VP and determining the brain regions and/or systems involved in its different behavioral effects, it may be possible to identify a specific receptor subtype target, drug treatment combination, or specific clinical contexts that may point toward a more successful treatment.</p>
</sec>
</abstract>
<kwd-group>
<kwd>ethanol</kwd>
<kwd>vasopressin</kwd>
<kwd>hypothalamus</kwd>
<kwd>amygdala</kwd>
<kwd>anxiety</kwd>
<kwd>alcohol intake</kwd>
<kwd>tolerance</kwd>
<kwd>clinical trials</kwd>
<kwd>antagonists</kwd>
<kwd>stress</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>